Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia

Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia

Show other versions (1)

Abstract Internal tandem duplication of Fms‐like tyrosine kinase 3 (FLT3/ITD) occurs in about 30% of acute myeloid leukemia (AML) and is associated with poor response to conventional treatment and adverse outcome. Here, we reported that human FLT3/ITD expression led to axis duplication and dorsaliza...

Full description

Bibliographic Details
Main Authors: Bai‐Liang He, Ning Yang, Cheuk Him Man, Nelson Ka‐Lam Ng, Chae‐Yin Cher, Ho‐Ching Leung, Leo Lai‐Hok Kan, Bowie Yik‐Ling Cheng, Stephen Sze‐Yuen Lam, Michelle Lu‐Lu Wang, Chun‐Xiao Zhang, Hin Kwok, Grace Cheng, Rakesh Sharma, Alvin Chun‐Hang Ma, Chi‐Wai Eric So, Yok‐Lam Kwong, Anskar Yu‐Hung Leung
Format: Article
Language:English
Published: Springer Nature 2020-03-01
Series:EMBO Molecular Medicine
Subjects:
acute myeloid leukemia
follistatin
internal tandem duplication of Fms‐like tyrosine kinase 3
Online Access:https://doi.org/10.15252/emmm.201910895

Internet

https://doi.org/10.15252/emmm.201910895

Similar Items